Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Part B Drugs Could Be Switched To Part D Under Trump Pricing Plan

Executive Summary

Bringing the hammer down on biopharma, HHS Secretary Azar says department could use demonstration projects to switch drugs from Medicare Part B to Part D.

You may also be interested in...



Democrats’ Drug Pricing Bills Echo Trump Ideas But Broad Republican Support Unlikely

Upcoming House Oversight Committee hearing on drug pricing offers a chance for fireworks, but broader prospects for new Democratic pricing legislation seem limited.

Democrat-Controlled House Will Turn Up The Volume On Drug Pricing

With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will likely need to dovetail with President Trump’s agenda to advance.

Democrat-Controlled House Will Turn Up The Volume On Drug Pricing

With US House of Representatives now controlled by Democrats, lower chamber of Congress will likely increase hearings and investigations into industry pricing practices, but any legislation will probably need to dovetail with President Trump’s agenda to advance.

Related Content

Topics

Latest News
See All
UsernamePublicRestriction

Register

PS123108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel